CO
COGZF.US Cogstate Limited
- Market cap
- USD 419M
- P/E
- 34.7x
- P/B
- 7.60x
- ROE
- 20.4%
- Dividend yield
- 0.54%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is COGZF.US undervalued?
Graham numberThe Graham number of Cogstate Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cogstate Limited fundamental analysis
No fundamental analysis for Cogstate Limited yet.
Cogstate Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cogstate Limited
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, …
Full company profileCogstate Limited financial statements
Cogstate Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 34.9M | 39.2M | 31.1M | 34.5M | 32.7M | 45.0M | 40.5M | 43.4M | 50.8M | 58.4M |
| Gross Profit | 18.7M | 22.0M | 14.5M | 15.2M | 17.9M | 26.7M | 21.6M | 24.7M | 30.7M | 33.9M |
| Operating Income | -493K | 248K | -8.34M | -2.81M | 3.83M | 10.9M | 2.25M | 6.17M | 10.8M | 12.2M |
| EBITDA | 284K | 1.13M | -4.66M | 119K | 8.21M | 13.1M | 5.69M | 9.89M | 16.9M | 19.2M |
| Net Income | -824K | -766K | -3.56M | -1.92M | 5.23M | 7.52M | 3.57M | 5.45M | 10.1M | 11.9M |
| EPS | -0.01 | -0.01 | -0.03 | -0.01 | 0.03 | 0.04 | 0.02 | 0.03 | 0.06 | 0.07 |
| Balance Sheet | ||||||||||
| Total Assets | 21.8M | 25.4M | 27.4M | 46.1M | 51.4M | 58.4M | 54.1M | 57.8M | 64.8M | 78.1M |
| Total Liabilities | 7.41M | 9.62M | 13.0M | 22.6M | 29.6M | 25.5M | 16.4M | 17.0M | 16.9M | 19.8M |
| Shareholders' Equity | 14.4M | 15.8M | 14.4M | 23.5M | 21.8M | 32.9M | 37.7M | 40.9M | 47.9M | 58.3M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 15.1M | 23.6M | 30.6M | 28.7M | 30.1M | 35.6M | 34.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.39M | -122K | -61.0K | 730K | 16.1M | 9.73M | - | - | - | - |
| Capital Expenditure | 1.10M | 481K | 515K | 510K | 625K | 422K | 2.21M | 1.89M | 3.07M | 6.31M |
| Free Cash Flow | 1.32M | -4.04M | -2.95M | -3.51M | 12.9M | 6.16M | -1.56M | 3.90M | 8.40M | 2.20M |
| Ratios | ||||||||||
| ROE | -5.7% | -4.8% | -24.7% | -8.2% | 24.0% | 22.8% | 9.5% | 13.3% | 21.2% | 20.4% |
| ROA | -3.8% | -3.0% | -13.0% | -4.2% | 10.2% | 12.9% | 6.6% | 9.4% | 15.7% | 15.2% |
| Net Profit Margin | -2.4% | -2.0% | -11.4% | -5.6% | 16.0% | 16.7% | 8.8% | 12.5% | 20.0% | 20.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cogstate Limited dividends
- Dividend yield
- 0.54%
- Forward dividend
- 0.03 USD
- Payout ratio
- 18.9%
- Ex-dividend date
- Aug 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 2.25M | 0.01 | 18.9% |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 110:109 on Oct 22, 2019.
Who owns Cogstate Limited
- Insiders 40.36%
- Institutions 16.50%
- Public & others 43.14%
- Shares outstanding 173M
- Free float 125M
Cogstate Limited company profile
- Company name
- Cogstate Limited
- Ticker
- COGZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 160
- Fiscal year end
- June
- Address
- 367 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9664 1300
- Website
- cogstate.com
About Cogstate Limited
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer's disease and dementia, preclinical Alzheimer's disease, pediatrics and rare disease, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, and sleep and mood disorders. It also designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments. In addition, it develops a tool for primary care physicians and/or hospitals to assess cognitive decline. Its technology and associated services are used to quantify the effect of disease and drugs, devices, or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The company serves biopharmaceutical companies, academic institutions, physicians, and patients. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
Cogstate Limited management
8- Mr. Bradley John O'Connor B.Bus, C.A.CEO, MD & Executive Director
- Mr. Darren Watson C.A.CFO & Joint Company Secretary
- Dr. Pamela Ventola Ph.D.Chief Science Officer
- Ms. Rachel ColiteExecutive VP of Clinical Trials
- Prof. Paul Maruff BBSc (Hons), Ph.D.Founder & Chief Innovation Officer
- Mr. Kenneth BillardChief Commercial Officer
- Mr. David James Franks BEc, C.A., F Fin, J.P.Joint Company Secretary · born 1970
- Dr. Luka Lucic Ph.D.Senior Director of Clinical Science in Psychiatry